학술논문

The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers
Document Type
Article
Source
In: Science Translational Medicine. (Science Translational Medicine, 31 January 2024, 16(731))
Subject
Language
English
ISSN
19466242
19466234